✦ LIBER ✦

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

✍ Scribed by Sandro Pignata; Sabino De Placido; Rosalbino Biamonte; Giovanni Scambia; Giovanni Di Vagno; Giuseppe Colucci; Antonio Febbraro; Marco Marinaccio; Alessandra Vernaglia Lombardi; Luigi Manzione; Giacomo Cartenì; Mario Nardi; Saverio Danese; Maria Rosaria Valerio; Andrea de Matteis; Bruno Massidda; Giampietro Gasparini; Massimo Di Maio; Carmela Pisano; Francesco Perrone

Book ID: 115010945
Publisher: BioMed Central
Year: 2006
Tongue: English
Weight: 265 KB
Volume: 6
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-6-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of weekly carboplatin a

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer: A Multicentre Italian Trial in Ovarian cancer (MITO-5) study

✍ Sandro Pignata; Enrico Breda; Giovanni Scambia; Carmela Pisano; Vittorina Zagone 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 208 KB

Safety of a 3-weekly schedule of carbopl

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

✍ Sandro Pignata; Giovanni Scambia; Antonella Savarese; Enrico Breda; Paolo Scollo 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 247 KB

Docetaxel and carboplatin as first-line

Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group

✍ J Pfisterer; A du Bois; U Wagner; J Quaas; J.U Blohmer; D Wallwiener; F Hilpert 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Topotecan versus treosulfan, an alkylati

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

✍ Werner Meier; Andreas du Bois; Alexander Reuss; Walther Kuhn; Sigrid Olbricht; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 545 KB

Randomized Phase III Study of Erlotinib

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

✍ Vergote, I. B.; Jimeno, A.; Joly, F.; Katsaros, D.; Coens, C.; Despierre, E.; Ma 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 189 KB

Randomised controlled trial comparing si

Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group

✍ Buda, A; Floriani, I; Rossi, R; Colombo, N; Torri, V; Conte, P F; Fossati, R; Ra 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 116 KB